Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm

Abstract Measurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is increasingly challenging to use OS as the primary endpoint if timely approval of novel agents is to b...

Full description

Saved in:
Bibliographic Details
Main Authors: Charlotte Pawlyn, Fredrik H. Schjesvold, David A. Cairns, L. J. Wei, Faith Davies, Omar Nadeem, Haifaa Abdulhaq, Maria-Victoria Mateos, Jacob Laubach, Katja Weisel, Heinz Ludwig, S. Vincent Rajkumar, Pieter Sonneveld, Graham Jackson, Gareth Morgan, Paul G. Richardson
Format: Article
Language:English
Published: Nature Publishing Group 2024-08-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-024-01109-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41408-024-01109-4

Similar Items